Welcome to our dedicated page for ARTIVION SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Jean F. Holloway, SVP & General Counsel of Artivion, Inc. (AORT), reported transactions on 08/25/2025. She exercised a stock option to acquire 10,000 shares at an exercise price of $11.03 per share and concurrently sold 10,000 shares at $44.37 per share. After these transactions she beneficially owned 172,129 shares. The option exercised relates to a grant with an $11.03 exercise price, originally exercisable beginning 11/08/2023 and expiring 11/08/2029; the option vests 33 1/3% per year starting on the first anniversary of the grant date.
Artivion, Inc. (AORT) Form 144 notice reports proposed sale of 10,000 common shares by an insider via Morgan Stanley Smith Barney LLC, with an aggregate market value of $443,700 and an approximate sale date of 08/25/2025. The form shows those shares were acquired and paid for on 08/25/2025 through a stock option exercise with cash payment. The filing also discloses two recent common-stock sales by JEAN F HOLLOWAY: 23,356 shares sold on 08/12/2025 for $1,004,605.97 and 8,748 shares sold on 05/27/2025 for $253,692.00. The filer affirms no undisclosed material adverse information.
James P. Mackin, President & CEO and director of Artivion, Inc. (AORT), reported a sale of common stock on 08/15/2025. The Form 4 shows he sold 12,500 shares at a weighted average price of $42.319 (prices ranged $42.25 to $42.585). After the transaction he beneficially owned 852,783 shares. The filing is signed 08/19/2025 and the reporting person notes availability of per-price sale details upon request.
Form 144 notice for Artivion, Inc. (AORT) shows a proposed sale of 12,500 common shares through RBC Capital Markets with an aggregate market value of $528,991. The filing lists the approximate sale date as 08/15/2025 and the shares outstanding as 47,183,658. The shares were acquired in open-market purchases: 5,000 shares on 11/13/2019 and 7,500 shares on 11/13/2019 (with payment dated 09/16/2020 for the second lot). The filer reports no sales in the past three months and makes the standard representation about material undisclosed information.
Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported securities transactions dated 08/12/2025. She exercised stock options covering 16,975 underlying shares with a conversion/exercise price of $26.24 (option grant dated 02/19/2021, vesting 33 1/3% per year and first exercisable on 02/19/2021). On the same date she sold 16,975 shares at a weighted-average price of about $43.011 and an additional 6,381 shares at about $43.018. The filings show her beneficial ownership moved from 195,485 shares to 178,510 and then to 172,129 shares following the reported transactions. Footnotes disclose the weighted-average sale price ranges and offer to provide per-price details on request.
John E. Davis, Chief Commercial Officer of Artivion, Inc. (AORT), exercised 10,802 stock options with an exercise price of $26.24 per share and acquired 10,802 common shares on 08/12/2025. He then sold the same 10,802 shares at a weighted-average price of $43.673, with reported sale prices ranging $43.470–$43.835.
Following these transactions Mr. Davis beneficially owns 208,778 shares. The exercised options were from a grant dated 02/19/2021 that vests 33 1/3% per year and expires 02/19/2027. The filing notes detailed per-price sale information is available upon request.
Artivion, Inc. (AORT) filed a Form 144 reporting a proposed sale of common stock. The filing shows 10,802 shares intended for sale on 08/12/2025 through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $471,752.51. The issuer's outstanding shares are listed as 47,183,658.
The securities were acquired on 08/12/2025 through a stock option exercise from the issuer and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Artivion, Inc. (AORT) has a Form 144 notice reporting a proposed sale of 23,356 common shares with an aggregate market value of $1,004,605.97. The sale is listed as occurring approximately on 08/12/2025 on the NYSE through Morgan Stanley Smith Barney LLC.
The filing shows how the shares were acquired: 6,381 as restricted stock on 02/19/2019 and 16,975 via a stock option exercise on 08/12/2025 paid in cash. The form also discloses multiple insider sales in May 2025 by JEAN F HOLLOWAY, including transactions on 05/21/2025 and 05/27/2025, each with listed share amounts and gross proceeds. The filer affirms no undisclosed material adverse information.
Juniper Investment-affiliated reporting persons amended their Schedule 13D to report a decrease in their beneficial ownership of Artivion, Inc. common stock to 1,864,449 shares, representing approximately 4.0% of outstanding shares as of the record date. Between June 17, 2025 and August 11, 2025 Juniper Targeted Opportunities, L.P. sold 233,715 shares in the open market for an aggregate sale price of approximately $9,540,725, which includes brokerage commissions. Percentages are calculated using 47,183,656 shares outstanding as of August 1, 2025.
The filing breaks out ownership by entity: Juniper Fund holds 1,473,656 shares (about 3.1%), Juniper Targeted Opportunities holds 377,308 shares (about 0.8%), and Juniper Multi-Strategy holds 13,485 shares (about 0.0%). Juniper Investment Company and the named managing members may be deemed to beneficially own the aggregate shares but disclaim ownership for other purposes. The amendment references a Joint Filing Agreement and a schedule of transactions as exhibits.
Amy Horton, Vice President and Chief Accounting Officer of Artivion, reported exercising 7,992 stock options and selling the same 7,992 shares on 08/08/2025. The options had an exercise price of $29.62 and the shares were sold at $38.49, producing an approximate per-share gain of $8.87. After these transactions she directly owns 146,651 shares.
The sale was effected pursuant to a 10b5-1 trading plan adopted March 13, 2025. The exercised options vest at 33 1/3% per year beginning on the first anniversary of the grant; the first exercisable date was March 5, 2020 and the options expire March 5, 2026.